Evidence map›Paper›PMID 34405025›Full record

ArticleJournal of Cancer2021

A Luminacin D Analog HL142 Inhibits Ovarian Tumor Growth and Metastasis by Reversing EMT and Attenuating the TGFβ and FAK Pathways.

Baojin Wang, Hanxuan Li, Xinxin Zhao, Wenjing Zhang, Guannan Zhao, Zhongzhi Wu, Ruitao Zhang, Peixin Dong, Hidemichi Watari, Gabor Tigyi and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Baojin WangDepartment of Gynecology and Obstetrics, Third Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Hanxuan LiDepartment of Pharmaceutical Sciences, College of Pharmacy, the University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Xinxin ZhaoDepartment of Gynecology and Obstetrics, Third Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Wenjing ZhangDepartment of Genetics, Genomics & Informatics, College of Medicine, the University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Guannan ZhaoDepartment of Pathology and Laboratory Medicine, College of Medicine, the University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Zhongzhi WuDepartment of Pharmaceutical Sciences, College of Pharmacy, the University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Ruitao ZhangDepartment of Gynecology and Obstetrics, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Peixin DongDepartment of Gynecology, Hokkaido University School of Medicine, Hokkaido University, Sapporo, Japan.
Hidemichi WatariDepartment of Gynecology, Hokkaido University School of Medicine, Hokkaido University, Sapporo, Japan.
Gabor TigyiCenter for Cancer Research, College of Medicine, the University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Wei LiDepartment of Pharmaceutical Sciences, College of Pharmacy, the University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Junming YueDepartment of Pathology and Laboratory Medicine, College of Medicine, the University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
University of Tennessee Health Science Center · USHokkaido University · JPCenter for Cancer Research · USFirst Affiliated Hospital of Zhengzhou University · CNThird Affiliated Hospital of Zhengzhou University · CN

Funding

Ligand Recognition by Phospholipid Growth Factor ReceptorsR01CA092160 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI TIGYI, GABOR J · 2001 to 2022
$5.9M
Selective Targeting Survivin for Cancer TherapyR01CA193609 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LI, WEI · 2016 to 2020
$1.9M
Role of MTF1 in ovarian cancerR21CA216585 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI YUE, JUNMING · 2018 to 2019
$385k
NCI NIH HHS R01 CA092160NCI NIH HHS R01 CA193609NCI NIH HHS R21 CA216585
6 · The paper itself

Abstract

Epithelial to mesenchymal transition (EMT) is known to contribute to tumor metastasis and chemoresistance. Reversing EMT using small molecule inhibitors to target EMT associated gene expression represents an effective strategy for cancer treatment. The purpose of this study is to test whether a new luminacin D analog HL142 reverses EMT in ovarian cancer (OC) and has the therapeutic potential for OC. We chemically synthesized HL142 and tested its functions in OC cells

Indexed as

ASAP1EMTFAKHL142Luminacin D analogmetastasisovarian tumor

Identifiers

PMID34405025
PMCPMC8364639
OpenAlexW3188628244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.